Infant Bacterial Therapeutics AB

Historical price data

IBT's mission is to pioneer live biotherapeutic products to prevent and treat life-threatening conditions in premature infants, a population with significant unmet medical needs. The company's core achievement is advancing its lead candidate, IBP-9414 (Lactobacillus reuteri), into late-stage development for necrotizing enterocolitis (NEC) and feeding intolerance, positioning it to potentially launch the first drug in this novel therapeutic class. Its strategy is intensely focused on neonatal care, with a pipeline built upon a proprietary platform of bacterial strains sourced from human breast milk and infant gut flora. With a public listing on Nasdaq Stockholm and a valuation near $660 million, IBT is a specialized pure-play in the emerging field of neonatal microbiome therapeutics.

Proprietary platform developing Live Biotherapeutic Products (LBPs) using specific, naturally occurring bacterial strains isolated from human breast milk and infant gut flora to prevent and treat severe diseases by restoring a healthy microbiome.

IBT has a clear first-mover advantage with no direct late-stage LBP competitors for NEC. The primary competition is the current standard of care, including off-label probiotic blends. Its key differentiator is the development of a single-strain, pharmaceutical-grade product with rigorous clinical validation, as opposed to unregulated probiotic supplements.